|
Re: Resverlogix to Participate in Leading Scientific Conferences
|
10
|
Resverlogix Corp.
|
Oct 29, 2021 09:54AM
|
|
Re: Resverlogix to Participate in Leading Scientific Conferences
|
5
|
Resverlogix Corp.
|
Oct 29, 2021 10:25AM
|
|
Re: Resverlogix Reports Filing of New Intellectual Property on Key Renal Protection and Glucose Control Markers
|
7
|
Resverlogix Corp.
|
Nov 02, 2020 09:54AM
|
|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
7
|
Resverlogix Corp.
|
Jun 22, 2020 01:36PM
|
|
Re: Resverlogix In Active Discussions With The Kingdom of Morocco’s Ministry of Health For The Launch Of COVID-19 Clinical Studies With First-In-Class Dru
|
1
|
Resverlogix Corp.
|
Nov 02, 2021 01:28PM
|
|
Re: Resverlogix In Active Discussions With The Kingdom of Morocco’s Ministry of Health For The Launch Of COVID-19 Clinical Studies With First-In-Class Dru
|
4
|
Resverlogix Corp.
|
Nov 01, 2021 12:23PM
|
|
Re: RESVERLOGIX CORP WTS 2021
|
5
|
Resverlogix Corp.
|
May 11, 2021 04:00PM
|
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
6
|
Resverlogix Corp.
|
Mar 26, 2020 02:53PM
|
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
5
|
Resverlogix Corp.
|
Mar 26, 2020 06:29PM
|
|
Re: Resverlogix Announces Voting Results from the 2024 Meeting of Shareholders and Closing of Debenture Extension
|
2
|
Resverlogix Corp.
|
Aug 01, 2024 11:27AM
|
|
Re: Resverlogix Announces Voting Results from the 2024 Meeting of Shareholders and Closing of Debenture Extension
|
3
|
Resverlogix Corp.
|
Aug 01, 2024 11:49AM
|
|
Re: Resverlogix Announces Voting Results from the 2024 Meeting of Shareholders and Closing of Debenture Extension
|
3
|
Resverlogix Corp.
|
Aug 01, 2024 12:41PM
|
|
Re: Resverlogix Announces Voting Results from the 2024 Meeting of Shareholders and Closing of Debenture Extension
|
3
|
Resverlogix Corp.
|
Aug 01, 2024 02:40PM
|
|
Re: RESVERLOGIX ANNOUNCES VOTING RESULTS FROM THE 2022 MEETING OF SHAREHOLDERS
|
7
|
Resverlogix Corp.
|
Jun 22, 2022 03:09PM
|
|
Re: Resverlogix Announces Publication on Apabetalone in Cardiovascular Therapeutics
|
5
|
Resverlogix Corp.
|
Aug 04, 2020 08:38AM
|
|
Re: RESVERLOGIX ANNOUNCES PUBLICATION OF KEY APABETALONE STUDY BETONMACE IN THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
|
3
|
Resverlogix Corp.
|
Mar 31, 2020 05:44PM
|
|
Re: RESVERLOGIX ANNOUNCES PUBLICATION OF KEY APABETALONE STUDY BETONMACE IN THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
|
1
|
Resverlogix Corp.
|
Mar 31, 2020 06:32PM
|
|
Re: RESVERLOGIX ANNOUNCES PUBLICATION OF KEY APABETALONE STUDY BETONMACE IN THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
|
3
|
Resverlogix Corp.
|
Mar 31, 2020 07:02PM
|
|
Re: RESVERLOGIX ANNOUNCES PUBLICATION OF KEY APABETALONE STUDY BETONMACE IN THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
|
4
|
Resverlogix Corp.
|
Mar 31, 2020 07:56PM
|
|
Re: RESVERLOGIX ANNOUNCES PUBLICATION OF KEY APABETALONE STUDY BETONMACE IN THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
|
5
|
Resverlogix Corp.
|
Mar 31, 2020 08:07PM
|
